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1. Introduction
Migraine represents the third cause of disability in the world-
wide population aged under 50 years. Facing this enormous
social impact, only onabotulinumtoxinA has been evaluated,
on serendipity basis, as effective chronic migraine preventa-
tive treatment [1]. Pharmacological research is now moving
important steps forward towards bridging the 30-year gap of
new preventative class drugs for migraine, with a new mole-
cule in its final phase of development: monoclonal antibodies
for calcitonin gene-related peptide (CGRP) or its receptors
(CGRPr) [2,3].
In the development pipeline of new drugs for the acute
treatment, there is only one innovative compound, lasmidi-
tan [4], while there are numerous devices and nutraceuticals
in both categories [5]. This is surely not the scenario that one
billion of migraine patients is hoping for from scientific
research, and a new call for action is required in order to
promote the study on new innovative drugs for the acute
treatment of migraine. This would reduce the personal, work-
ing, and pharmaco-economic impact and the public health
expenditure caused by this pathology, that could be appro-
priately defined as a social disease from now on.
2. Travelling from NSAIDs to triptans to CGRP
A quarter of a century has passed since the last spring of
migraine acute treatment, when the progenitor or triptans,
sumatriptan, came to light. Afterwards, the triptan family saw
the development of other six members decreeing the end of
ergot derivate [6]. This triptan event was a turning point for all
primary headaches, who gained then a cultural and scientific
attention never seen before. Afterwards, researchers’ attention
was driven towards comparing the effectiveness of the seven
triptan brothers, alone or in combination with NSAIDs. The
debate revolved around safety, efficacy, consistency, drug–
drug interactions with prophylactic drugs, pharmacokinetics/
pharmacodynamics, new delivery pathways, extension of this
pharmacological class to the population aged under 18 or
over 65 years, evaluation of common adverse events, disability
levels [6–12]. Notwithstanding, only 27% of migraine patients
receive a correct diagnosis and only 17% of them takes trip-
tans for a crisis [13,14]. Therefore, two different studies in Italy
and Australia show how in a real population of migraine
patients only the great minority of them receive a correct
advice for the treatment of the crisis [13,14].
In this long period of time, the scientific focus has been
progressively oriented towards the definition of migraine
chronic forms, and this brought to light another plague,
known but concealed or labeled as exclusively psychiatric,
patients’ drug overuse for frequent migraine attacks [15]. It
has been much and elusively debated, overtime, if drug over-
use deserves its own slot in the classification or it is only an
inevitable complication of chronic migraine [16]. What matters
today is that triptans contributed to this alarming and harmful
phenomenon of overuse. Monoclonal antibodies mark the
entrance into a new era of migraine treatment, and the ones
dedicated to prophylaxis treatment are close to approval.
3. Preventative treatment is now moving forward
The scenario revolving around migraine is populated today by
various actors: the new pharmacological class of monoclonal
antibodies, subcutaneous or intravenous, for CGRP (CGRP
MoAbs) or its receptor (CGRPr MoAbs), and the small-molecule
oral CGRPr antagonists [2,3].
While migraine preventative treatment shows a developing
florid asset, with 37% new drugs versus a reconsideration of
31% drugs already known (Figure 1), in acute treatment, the
prevalence of new therapeutic opportunities decreases dra-
matically to 15% of new molecules being developed
(Figure 2). At the same time, devices are strongly represented
in 20% of preventative treatments and they even raise up to
28% in acute treatments.
This is what results from a search of randomized control
trials (RCTs), registered on ClinicalTrials.gov, using the Mesh
Terms ‘acute migraine treatment,’ ‘preventative migraine
treatment,’ group eligibility criteria ‘Adult (18–65)’, First
Received ‘From 01/01/2012 to 03/10/2017’, Last Updated
‘From 01/01/2012 to 03/10/2017’ [17].
Unfortunately, for primary headache research, new RCTs
are lacking [18]; therefore, we are still in the phase when old
molecules are rehabilitated on the basis of a real-world
evidence.
The request for innovative molecules for acute migraine
treatment relies today on lasmiditan, the most important
advancement in this sector [4] even if still presenting issues
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to be investigated. Lasmiditan is a new 5-HT receptor agonist
with high affinity and selectivity for the 5-HT1F receptor. Its
chemical structure, as well as the pharmacological profile, is
different from triptans.
The indole structure of triptans, identical to the neurotransmit-
ter 5-HT, is replaced by a pyridinoyl–piperidine scaffold, which is
not found in any other antimigraine classes. From the mechanism
of action point of view, lasmiditan efficacy in migraine is mediated
through a nonvascular, first neural pathway, with a loss of the
typical vasoconstrictor activity expressed by triptans [4].
4. Meanwhile, acute migraine treatment loses
ground
The ideal migraine treatment is still far, and it seems that there
is not a resolved trend to cover the needs of 83% migraine
patients never treated with triptans [13,14]. Precision medicine
applied to migraine shows structural weaknesses, based on
the variety of the genes involved and the well-known multi-
factorial nature of migraine itself [19,20].
Acute migraine treatment is an aging therapeutic area that
faces enormous needs in terms of actively working population
[21], and it might produce, at least for low- and medium-
frequency brackets, an individual, social, economic, produc-
tive, and public health benefit of incommensurable value,
given the well-known economic damage that both chronic
and episodic migraine produce in the National Health
Systems all over the Europe [22].
5. Expert opinion section
Migraine results to be one of the most spread pathologies in
the world (14% of the entire population, one billion of
patients), causes disability in people aged under 50 years,
and ranks third among all illnesses, but it is correctly diag-
nosed only in 27% of the cases and adequately treated with
triptans in barely 46% of them. Unfortunately, the majority of
migraine patients treat their crisis with NSAIDs combined with
or not with different compounds, such as caffeine, ergot deri-
vatives, barbiturates, etc., carrying themselves towards a
chronicity complicated by drug overuse. This evident thera-
peutic gap on the appropriateness of acute migraine treat-
ment is scarcely filled by the development of new compounds,
except lasmiditan. In fact, an accurate analysis of acute drugs
actually being developed reveals that while two-third of pre-
ventative treatment consists in new compounds, barely one-
sixth of acute treatment refers to new chemical compounds.
Monoclonal antibodies towards CGRP or its receptor (CGRPr)
will be one additional prophylactic treatment option, useful to
an easier treatment of acute migraine attacks by reducing
their frequency and mitigating the pain severity.
This unmet need requires new ideas that, starting from
physiopathological mechanisms, can identify the target for a
simple, rapid, and safe option in acute treatment.
Therefore, today, the unique possible reply to the question
‘Acute Treatment of Migraine: Quo Vadis?’ is, unfortunately, ‘I
don’t know.’
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